A series of isothiazolones that inhibit pro-(matrix metalloproteinase) (proMMP) activation but do not inhibit the active enzyme are effective as cartilage protectants in bovine nasal cartilage organ culture, preventing interleukin-1 (IL-1)-induced proteoglycan (aggrecan) degradation without affecting its synthesis. These compounds were found to bind to prostromelysin (proMMP-3) in a non-dialysable and stoichiometric manner. Preincubation with cartilage-protectant isothiazolones prevented the binding of [14C]iodoacetamide to Cys75 of the MMP-3 propeptide, suggesting that the activity of these compounds involves their binding to the Cys75 of the MMP zymogen. Studies following chymotrypsin activation of proMMP-3 by SDS/PAGE indicated that altered processing of the 57 kDa zymogen to the active form occurred in the presence of compound. The 53 kDa intermediate seen on normal activation was not formed; instead a different intermediate appeared with a molecular mass of approx. 46 kDa. N-terminal sequence analysis indicated that this intermediate was formed by cleavage at the putative 4-aminophenylmercuric acid cleavage site. Importantly the 45 kDa active MMP-3 species formed in the presence of compound was one amino acid residue shorter than the native MMP-3. These results suggest that the inhibition of cartilage proteoglycan degradation by isothiazolones might be due to their ability to bind to the Cys75 in the propeptide region of the MMP zymogen and interfere with its normal activation process.
Skip Nav Destination
Article navigation
September 1996
-
Cover Image
Cover Image
- PDF Icon PDF LinkTable of Contents
Research Article|
September 01 1996
Isothiazolones interfere with normal matrix metalloproteinase activation and inhibit cartilage proteoglycan degradation
Elizabeth C ARNER;
Elizabeth C ARNER
*
*To whom correspondence should be addressed.
Search for other works by this author on:
Michael A PRATTA;
Michael A PRATTA
1Inflammatory Diseases Research, The DuPont Merck Pharmaceutical Company, Experimental Station, Wilmington, DE 19880-0400, U.S.A.
Search for other works by this author on:
Bruce FREIMARK;
Bruce FREIMARK
1Inflammatory Diseases Research, The DuPont Merck Pharmaceutical Company, Experimental Station, Wilmington, DE 19880-0400, U.S.A.
Search for other works by this author on:
Michael LISCHWE;
Michael LISCHWE
1Inflammatory Diseases Research, The DuPont Merck Pharmaceutical Company, Experimental Station, Wilmington, DE 19880-0400, U.S.A.
Search for other works by this author on:
James M TRZASKOS;
James M TRZASKOS
1Inflammatory Diseases Research, The DuPont Merck Pharmaceutical Company, Experimental Station, Wilmington, DE 19880-0400, U.S.A.
Search for other works by this author on:
Ronald L MAGOLDA;
Ronald L MAGOLDA
1Inflammatory Diseases Research, The DuPont Merck Pharmaceutical Company, Experimental Station, Wilmington, DE 19880-0400, U.S.A.
Search for other works by this author on:
Stephen W WRIGHT
Stephen W WRIGHT
1Inflammatory Diseases Research, The DuPont Merck Pharmaceutical Company, Experimental Station, Wilmington, DE 19880-0400, U.S.A.
Search for other works by this author on:
Biochem J (1996) 318 (2): 417–424.
Article history
Received:
October 11 1995
Revision Received:
February 19 1996
Accepted:
April 26 1996
Citation
Elizabeth C ARNER, Michael A PRATTA, Bruce FREIMARK, Michael LISCHWE, James M TRZASKOS, Ronald L MAGOLDA, Stephen W WRIGHT; Isothiazolones interfere with normal matrix metalloproteinase activation and inhibit cartilage proteoglycan degradation. Biochem J 1 September 1996; 318 (2): 417–424. doi: https://doi.org/10.1042/bj3180417
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.